Suppr超能文献

左乙拉西坦与吡拉西坦对儿童屏气发作疗效的比较:一项随机对照临床试验

The Comparison of Levetiracetam and Piracetam Effectiveness on Breath-Holding Spells in Children: A Randomized Controlled Clinical Trial.

作者信息

Ghazavi Mohammad Reza, Salehi Mohammad Mehdi, Nasiri Jafar, Yaghini Omid, Mansouri Vahid, Hoseini Neda

机构信息

Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Department of Pediatrics, Isfahan University of Medical Sciences, Isfahan, Iran.

出版信息

Adv Biomed Res. 2021 Dec 25;10:47. doi: 10.4103/abr.abr_234_20. eCollection 2021.

Abstract

BACKGROUND

We aimed to compare the effectiveness of Levetiracetam and Piracetam on the severity and frequency of spells in children with severe breath-holding spells (BHS), i.e. bening, paroxysmal, and nonepileptic events that are common in early childhood.

MATERIALS AND METHODS

This study is a randomized controlled clinical trial in 71 children from 6 months to 6 years of age with BHS. They were randomly assigned to the two study groups (Levetiracetam and Piracetam group). The frequency and severity of BHS and the response to treatment were recorded on monthly visits during our 3 months follow-up.

RESULTS

There was a significant decline in the average number of frequency of spells before and after 3 months of treatment in each group in this study. Levetiracetam had significant effects on the average incidence of the loss of consciousness and seizure-like movements in our study, while Piracetam had no significant effect on the loss of consciousness. Our result showed better response in the Levetiracetam group (88.9% partial or complete response after treatment) compared with the Piracetam group (77.1% partial or complete response after treatment); however, it was not significant. It seems that Levetiracetam had better effect than Piracetam in some aspects in the treatment of BHS.

CONCLUSIONS

Both Piracetam and Levetiracetam are safe and had significant effects on the frequency of BHS in our study, however, levetiracetam showed superior effects on the severity of BHS.

摘要

背景

我们旨在比较左乙拉西坦和吡拉西坦对患有严重屏气发作(BHS)儿童发作的严重程度和频率的疗效,BHS是一种常见于幼儿期的良性、阵发性且非癫痫性事件。

材料与方法

本研究是一项针对71名6个月至6岁患有BHS儿童的随机对照临床试验。他们被随机分配到两个研究组(左乙拉西坦组和吡拉西坦组)。在我们3个月的随访期间,每月就诊时记录BHS的频率和严重程度以及对治疗的反应。

结果

本研究中每组治疗3个月前后发作的平均频率均有显著下降。在我们的研究中,左乙拉西坦对意识丧失和癫痫样运动的平均发生率有显著影响,而吡拉西坦对意识丧失无显著影响。我们的结果显示,与吡拉西坦组(治疗后部分或完全缓解率为77.1%)相比,左乙拉西坦组(治疗后部分或完全缓解率为88.9%)的反应更好;然而,差异不显著。在BHS的治疗中,左乙拉西坦在某些方面似乎比吡拉西坦效果更好。

结论

在我们的研究中,吡拉西坦和左乙拉西坦均安全,且对BHS的发作频率有显著影响,然而,左乙拉西坦在BHS的严重程度方面显示出更好的效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d2e/8781912/7d59525cb137/ABR-10-47-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验